Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 6/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26923326 | 0.98 | TSHR (0.55) | TSHRL3MBTL1ZDHHC20EPHX2CYP2C19 | |
| SCHEMBL26923902 | 0.94 | TSHR (0.58) | TSHRL3MBTL1ZDHHC20EPHX2 | |
| SCHEMBL31664097 | 0.91 | TSHR (0.55) | TSHRL3MBTL1ZDHHC20EPHX2 | |
| SCHEMBL4173227 | 0.86 | TSHR (0.52) | TSHRL3MBTL1ZDHHC20 | |
| SCHEMBL22609473 | 0.84 | TSHR (0.38) | TSHRL3MBTL1EPHX2CYP2C19 | |
| SCHEMBL13736171 | 0.83 | TSHR (0.48) | TSHRL3MBTL1 | |
| SCHEMBL20840269 | 0.83 | TSHR (0.48) | TSHRL3MBTL1 | |
| SCHEMBL13738486 | 0.83 | TSHR (0.48) | TSHRL3MBTL1 | |
| SCHEMBL998277 | 0.83 | TSHR (0.48) | TSHRL3MBTL1 | |
| SCHEMBL25372454 | 0.81 | ZDHHC20 (0.38) | TSHRZDHHC20EPHX2CYP2C19ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | MAKRIYANNIS ALEXANDROS (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | MAKRIYANNIS ALEXANDROS (US) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | CNR1, CNR2, CHRND | TSHR 1033/4885L3MBTL1 4013/4885ZDHHC20 2380/4885 |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | CNR1, CNR2, CHRND | TSHR 1105/4885L3MBTL1 4299/4885ZDHHC20 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.